that cause hemorrhagic fever (HF) as The CDC and NIAI() have classified the filoviruses and arenaviruses promlsing monovalent HF virus vaccines based on Category A priority pathogens. Recently1 we developed single HF virus glycoproteln (GP). We recombinant vesicular stomatitis virus (rVSV). Each vaccine expresses a Ebola virus (EBOV);2) Marburg demonstrated that these vaccines can protect nonhuman primates agaInst: 1) vaccines. The goal of this proposal is to virus (MARy);or 3) Lassa virus (LASV) when used as single-injection HF viral genes and provide broad develop a multiyaleni rVSV vaccine that can express up to four different Specifically, we will: spectnJm immunity to the Category A HF viruses that occur in Africa. vector. For EBOV previous (1) Sele?t HF viral giycoproteins for incorporation into a multivalent vaccine will require inclusion of both Zaire and studies suggest that protection against the Zaire and Sudan species o?6<22. mom ;If oar to- y?0 < Ebola, Marburg, and Lassa viruses areenigmatic emerging pathogens that cause severe HF in humans and nonhuman primates. Outbreaks occur regularly in the case of Lassa and sporadically in the case of the flioviruses in parts of Africa with human case fatality rates ranging between 15 and 90 percent. Currently, there are no licensed vaccines or treatments against these agents. The multivalent vaccine strategy proposed here may well represent an effective countermeasure for preventing filovirus and Lassa infection. iii ='0 0 2 400 3-_ aftPublic Health Relevance
